Commentpublierenpsycho-oncologie?

AnneBrédartPsychologue,PhD,HDR

UnitédePsycho-Oncologie

CongrèsSFPO22novembre2017

14h-18h

Pourquoiécrire?• Bâtirplusdeconnaissance• Partagerdelaconnaissance• Dénoncerdeserreurs• Montrerdelacrédibilité• Soutenirunerecherchedefinancement• Obtenirunposte• Apprendre• Etablirdesrelationsintéressantes• ….

Freinsàl’écriture

• Manqued’expérience• Mauvaiseshabitudesd’écriture• Anxiété• Perfectionnisme• Manquedeconfiance• Peurdel’échec• Résistanceauxcritiques• …

Alibis

• Manquedetemps• Manquededocumentation• Manqued’outils• Manqued’inspiration

Leviers• Travailleravecdescollègues• Assureruncadrematérieladéquat• Projetréaliste,àadaptersinécessaire• Etremotivé– Objectifsprécis– Progrèsrégulier– Persévérer

Préalables• Choixd’unsujetderechercheoriginal,pertinent,utile,contemporain/avant-garde

• Elaborationd’unprotocolederechercherigoureux– Méthodologiederecherche

• Recherchedefinancement– Appelsd’offre

• Soumissionauxinstancesrèglementaires• Collecteetgestiondesdonnées• Extractiondesdonnées,nettoyage• Analyse• Tracersesdémarches– Journaldebord

Ecriture• Ecriredèsledébut– Introduction–Méthode

• Suivrelalittérature• Revoir/réécrireaufildel’analyse,del’intégrationdesdonnéesdelalittérature

• Fairerelirepremierjet

Typedepublication

• Articlescientifique• Thèse• Livreacadémique• Livregénéral• Français/Anglais

Format(1)Quelcontenude…:• Abstract?• Introduction(contexte,rationneldesquestionsposées)?

• Méthode(?• Résultats(sansjugement)?• Discussion?• Conclusion?• Implicationscliniques?

Format(2)Quelleforme…:• Titres,sous-titres• Résultats– F(1,136)=4.86,MSE =3.97,p =.029,ὴ2=.03–

• Références– StyleAPA,Harvard…

• Tableaux,figures

Style• Phrasecourte• Texteconcis• Clair• Direct• Logique• Facileàsuivre(assurersalecture)• Facileàcomprendre(pédagogique)

Lettred’accompagnement

Pourquoiunarticleestrejeté?

• Inadaptéaujournal• Inadéquat,incomplet– Détailssurlapopulation,lesinstruments,letyped’analyse

• Manquedevaliditéinterne/externe• Surinterprétationdesrésultats• Ecritureconfuse,difficileàsuivre

EXPÉRIENCETRAVAILLERAVECDESCO-AUTEURS

Règlesdepublication

• Rôledesco-auteurs• Ordredesnoms• Collaboration/cadeau• Auteurfantôme• Conflitsd’intérêt• Fraude/plagiat

EXPÉRIENCEREJETIMMÉDIAT

DearDr. Brédart:

ThankyouforyoursubmissiontoJournalofClinicalOncology.Ihavereadyourmanuscriptinfulldetail.

Iamsorrytoreportthatweareunabletoacceptyourmanuscriptforpublication.Manyconsiderationsfactoredintoourdecision.Amongtheseconsiderationsisconcernthattheresultsofthisqualitativestudyaretoopreliminarytoinformoncologypractice. OurfeelingisthatthismanuscriptwouldbemoreappropriateforanotherjournalthatfocusestoagreaterextentthanJCOoninitialqualitativefindingsinoncology(e.g.,SupportiveCareinCancer).JournalofClinicalOncologyreceivesanaverageof5,000submissionsperyear,ofwhichmorethan3,000areOriginalReports,andlessthan13%oftheseareultimatelyacceptedforpublication.Inviewofthemanymanuscriptsthatwereceiveforconsideration,itissometimesnecessarytomakeaneditorialdecisionastowhetherapaper'spriorityishighenoughtowarrantfullreview.Rejectionofamanuscriptbaseduponpriorityconsiderationsshouldnotbetakentoimplythatthestudylacksmerit.Rather,theexpeditedreviewprocessisultimatelydesignedtopermityoutomorerapidlyresubmitthepapertoamoreappropriatejournal.

Sincerely,

PaulJacobsen,PhDAssociateEditorJournalofClinicalOncology

EXPÉRIENCERÉVISIONMAJEURE

Reviewer(s)'CommentstoAuthor:Reviewer:1

CommentstotheAuthorThemanuscriptdescribesanimportantareaofresearchintopatients'tolerabilityofMTA-relatedside-effectsusingqualitativemethodologywhichwasclearlyoutlined. Thepaperwouldbenefitfromagreaterclarityofexpression. Forexampletheabstractcontainssentenceswhicharedifficulttofollowespeciallytheconcludingsentence. Adescriptionofeligiblepatientgroupswouldbeadvisable,forexample,theabstractcouldoutlinethatpatientswithdifferentcancersreceivingMTAswereeligibleforinclusion. AnoutlinefortherationaleforincludingpatientsonMTAseitherasmonotherapy,dualMTAorincombinationwithchemotherapywhileexcludingthosereceivingMTAswithradiotherapy couldhavebeenprovided. Sideeffectsdescribedmightbeaconsequenceofthechemotherapy.Inaddition,therationaleforincludingpatientsstillontreatmentandthoseforwhomtreatmenthasbeendiscontinuedcouldbeclearlyoutlined.Therecouldbediscussionofdifferentperceptionsofsideeffectsaccordingtotreatmentsetting(metastaticoradjuvant).Finally,amoredescriptiveandcomprehensiveoverviewofthefindingswithinthetextcouldhavebeenprovided- Table2.providesillustrativeexcerptsbutquotestosupportargumentswithinthetextcouldhavebeenprovided,forexamplewithinthediscussionofsocialrepercussionsofsideeffects.

RéponseàR1

Reviewer:2

CommentstotheAuthor

CommentstotheAuthorsVeryimportantstudy!ResultsVeryinterestingandimportantresults!However,youneedtogiveamorethoughtfulpictureofthelivedexperiencesandaddmorequotestovalidateyourresults(morethanthetable).Forexample;“…theyfeltsymptomimprovementandreductioninside-effects...”(page9),Iwouldliketoknowwhatthepatientssaid,becausewhenIreadthequotesinyourtable,Ionlyreadaboutdifficultside-effects.Theresultsectionwouldalsobenefitbyincludingsomequotesaboutthepatients’sideeffectsregardingfrequency.Atp.8:“patientsdescribedasthemostintolerable,unacceptableorunbearable…”Youneverdescribewhatisseenasunbearableside-effectsforpatients?Lateryouusewordsliketolerable,unpleasant,bothersome,etc.Isthissomethingelsethanintolerable,unacceptableorunbearable?

DiscussionIthinkyouhavetheoreticalandclinicalimplicationsthatareunderdevelopedinyourdiscussionsectionandshouldbefurtherextractedfromissuesofrelevancetoEJCCreaders.Asuggestionistostartthediscussionsectionwithyourprimaryresultsinmaximum2-3linesClinical:Arepatientswellinformed,dotheyunderstandthenatureandaimofphase1trials?Sincetheyunderestimatetheside-effectsandareafraidofbeingdroppedoutand,therefore,areholdingout,aretheyrelevanttreated?Ethical:Ifpatientswithseverecancerattheendoflifechoosetobetreatedinanaggressiveway– asalastchanceand,ifyouthenhaveinmindthattheaimofphase1trialsaretoidentifytoxicityprofile,thequestionmustbeasked– istheindividualtolerabilitydefinitionrelevant?Isitpossibletousesuchadefinitioninsuchsetting?Whatabouttherapeuticmisconceptionandthefactthatpatientspreferredphysicianstomakethedecisionfordiscontinuation.Isitaproblemthatthosewhodiscontinuedtrialparticipationmaybearesufferingfromlong-termside-effects,inadditiontoloosingtheirlasthope?Scientific:Theremightbeariskofbiasandincorrectresults(underreportedside-effects,tohighprescribeddrugs,unnecessaryadverseside-effects,whichalsoaffectphase2participants).Isthenthedefinitionofmedicaltolerabilityadequate?Isitpossibletoprovideanexcellentsafetyprofile,withalowincidenceofsideeffects?Yousaythat”patientsmostlyreportedacceptabletreatmenttolerance”(page11).Whataboutthosewhodiscontinuedthetrial?Clinicalimplicationsshouldbeadded.Whatcanwelearnfromyourresults?

RéponseàR2

Ressources• PublicationmanualoftheAPA,2010.

• Bragge,BMCMedResMeth,2011:TheGlobalEvidenceMappingInitiative:scopingresearchinbroadtopicareas.

• Baumeister,Rev Gen Psy,1997:Writing narrativereview.

• O'Brien,Acad Med,2014:Standardsforreportingqualitativeresearch:asynthesisofrecommendations.

• Liumbruno,BloodTransfus ,2013:Howtowriteascientificmanuscriptforpublication.

• Moher,BMJ,2009:Preferredreportingitemsforsystematicreviewsandmeta-analyses:thePRISMA statement.

• vonElm,AnnInterMed,2007:TheStrengtheningtheReportingofObservationalStudiesinEpidemiology(STROBE)statement:guidelinesforreportingobservationalstudies.